-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech's CM24 Shows Up To 90% Reduction In Death Risk In Pancreatic Cancer Patients, Biomarker Insights To Drive Next Phase 2b Study

Benzinga·04/30/2025 11:08:30
Listen to the news
  • Statistically significant efficacy in biomarker subgroup analyses was observed:
  •  
    • 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup
    • 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup
    • 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score (CPS) subgroup
  • The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study